Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Down 39.8% in December

Silexion Therapeutics Corp (NASDAQ:SLXN) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 47,547 shares, a decline of 39.8% from the December 15th total of 78,920 shares. Based on an average daily volume of 57,964 shares, the short-interest ratio is currently 0.8 days. Approximately 1.6% of the shares of the company are sold short. Approximately 1.6% of the shares of the company are sold short. Based on an average daily volume of 57,964 shares, the short-interest ratio is currently 0.8 days.

Silexion Therapeutics Price Performance

NASDAQ SLXN traded down $0.17 during trading on Friday, hitting $2.27. 36,498 shares of the stock traded hands, compared to its average volume of 55,522. The company has a quick ratio of 3.97, a current ratio of 3.97 and a debt-to-equity ratio of 0.22. Silexion Therapeutics has a 12-month low of $1.65 and a 12-month high of $51.75. The firm has a 50-day simple moving average of $2.49 and a 200-day simple moving average of $5.32. The company has a market capitalization of $7.11 million, a P/E ratio of -0.20 and a beta of -0.03.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Wednesday, November 12th. The company reported ($2.88) EPS for the quarter, beating analysts’ consensus estimates of ($3.40) by $0.52.

Analysts Set New Price Targets

SLXN has been the topic of several recent research reports. Zacks Research raised Silexion Therapeutics to a “hold” rating in a research note on Tuesday, December 16th. Litchfield Hills Research started coverage on shares of Silexion Therapeutics in a report on Monday, December 15th. They issued a “buy” rating for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Wednesday, October 8th. Finally, Wall Street Zen downgraded shares of Silexion Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $75.00.

About Silexion Therapeutics

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.